Dr. Reddy’s Laboratories Limited is one of India’s leading pharmaceutical companies, recognized globally for its high-quality medicines and innovative healthcare solutions. The company develops, manufactures, and markets a wide range of pharmaceutical products, including generics, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products. With a focus on affordable and accessible healthcare, Dr. Reddy’s serves patients in over 50 countries. As of November 29, 2024, the Dr Reddy share price on the NSE is ₹1202. Below are the projected Dr Reddy share price target for the years 2025, 2030, 2035 And 2040.
Additionally, feel free to join our – Tele-(g)ram) where we share Fast stock market news and updates➥https://bit.ly/TradeWatch360
Dr Reddy Company Overview
Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy’s Laboratories Limited is a pioneer in the pharmaceutical industry. The company’s portfolio spans therapeutic areas such as oncology, gastroenterology, dermatology, cardiovascular diseases, and anti-infectives. Its offerings include complex generics and differentiated formulations, backed by robust research and development capabilities. Driven by its mission of “Good Health Can’t Wait,” Dr. Reddy’s Laboratories combines cutting-edge science, operational excellence, and sustainability initiatives to enhance patient outcomes and improve access to affordable healthcare worldwide.
| Company type | Public |
| Traded as | NSE: DRREDDY BSE: 500124 NYSE: RDY NSE NIFTY 50 constituent |
| ISIN | INE089A01023 |
| Industry | Pharmaceuticals |
| Founded | 1984 (40 years ago) |
| Founder | Anji Reddy |
| Headquarters | Hyderabad, Telangana, India |
| Area served | Worldwide |
| Key people | G. V. Prasad (Co-Chairman & MD) Kallam Satish Reddy (Chairman) Erez Israeli (CEO) |
| Products | Pharmaceuticals Generic drugs Over-the-counter drugs Vaccines Diagnostics Biologics Dietary supplements |
| Revenue | ₹28,905 crore(US$3.5 billion) (FY24) |
| Operating income | ₹7,201 crore(US$860 million) (FY24) |
| Net income | ₹5,577 crore(US$670 million) (FY24) |
| Total assets | ₹38,863 crore(US$4.7 billion) (FY24) |
| Total equity | ₹28,254 crore(US$3.4 billion) (FY24) |
| Number of employees | 24,832 (March 2023) |
| Website | www.drreddys.com |
Dr Reddy Share Price Target 2025-2040 Forecast
| Year | Year High Target (₹) | Year Low Target (₹) | Year-End Target (₹) |
| 2024 | ₹1420 | ₹1050 | ₹1320 |
| 2025 | ₹1650 | ₹1230 | ₹1500 |
| 2026 | ₹1910 | ₹1450 | ₹1850 |
| 2027 | ₹2300 | ₹1720 | ₹2210 |
| 2028 | ₹2730 | ₹1950 | ₹2600 |
| 2029 | ₹3050 | ₹2540 | ₹2880 |
| 2030 | ₹3470 | ₹2790 | ₹3280 |
| 2035 | ₹5640 | ₹3020 | ₹5250 |
| 2040 | ₹8150 | ₹4850 | ₹7850 |
Technical Analysis for Dr. Reddy’s Laboratories Ltd
Dr Reddy Share Price Target 2025
| Year | 1st Target | 2nd Target |
| 2025 | 1480 | 1650 |
Dr. Reddy Laboratories, a leading pharmaceutical company, is well-positioned to capitalize on its strong portfolio of generic and branded medicines, supported by expanding global demand. With a focus on innovation and strategic market expansion, the company’s share price for 2025 is projected at a first target of ₹1480 and a second target of ₹1650.
Read More: IFCI Share Price Target 2025, 2030, 2035, 2040
Dr Reddy Share Price Target 2026
| Year | 1st Target | 2nd Target |
| 2026 | 1800 | 1910 |
By 2026, Dr. Reddy is expected to strengthen its position with new product launches, growth in emerging markets, and increased R&D investments. The first target share price for 2026 is estimated at ₹1800, with a second target of ₹1910, showcasing its consistent growth trajectory.
Dr. Reddy’s Laboratories Ltd Share Price Target 2027
| Year | 1st Target | 2nd Target |
| 2027 | 2150 | 2300 |
With continued investments in biosimilars and oncology drugs, Dr. Reddy’s is likely to see substantial growth by 2027. The first target share price is projected at ₹2150, with a second target of ₹2300, reflecting its ability to deliver strong financial performance.
Dr Reddy Share Price Target 2028
| Year | 1st Target | 2nd Target |
| 2028 | 2550 | 2730 |
As Dr. Reddy’s expands its global footprint and strengthens its pipeline of complex generics and proprietary drugs, its share price is expected to grow further. For 2028, the first target share price is estimated at ₹2550, with a second target of ₹2730.
Dr Reddy Share Price Target 2029
| Year | 1st Target | 2nd Target |
| 2029 | 2950 | 3050 |
By 2029, the company’s strategic initiatives and focus on innovation are expected to drive robust growth. The first target share price is projected at ₹2950, with a second target of ₹3050, indicating sustained market leadership.
Dr Reddy Share Price Target 2030
| Year | 1st Target | 2nd Target |
| 2030 | 3200 | 3470 |
Dr. Reddy’s is anticipated to maintain its growth momentum by 2030, leveraging its diversified portfolio and global presence. The first target share price is estimated at ₹3200, with a second target of ₹3470, underscoring its resilience in the competitive pharmaceutical industry.
Dr Reddy Share Price Target 2035
| Year | 1st Target | 2nd Target |
| 2035 | 4900 | 5640 |
Over the long term, Dr. Reddy’s is likely to benefit from advancements in pharmaceutical technologies and increased global healthcare spending. By 2035, the first target share price is projected at ₹4900, with a second target of ₹5640, reflecting significant growth potential.
Read More: Piccadily Agro Share Price Target 2025, 2030, 2035, 2040
Dr Reddy Share Price Target 2040
| Year | 1st Target | 2nd Target |
| 2040 | 7500 | 8150 |
By 2040, Dr. Reddy’s Laboratories is expected to achieve remarkable growth, supported by a strong focus on innovation, sustainability, and market expansion. The first target share price is estimated at ₹7500, with a second target of ₹8150, highlighting its robust long-term prospects.
Dr Reddy Fundamentals
| Metric | Value |
| Market Cap | ₹1,00,322 Cr |
| P/E Ratio (TTM) | 18.79 |
| P/B Ratio | 3.26 |
| Industry P/E | 37.36 |
| Debt to Equity | 0.16 |
| Return on Equity (ROE) | 17.36% |
| EPS (TTM) | 63.98 |
| Dividend Yield | 0.67% |
| 52 Week High | ₹1074 |
| 52 Week Low | ₹1421.5 |
| Book Value | 368.53 |
| Face Value | 1 |
Dr. Reddy’s Laboratories Ltd Financial Results
| Value In ₹Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
| Sales | 19,048 | 21,545 | 24,670 | 28,011 | 30,085 |
| Expenses | 15,173 | 17,778 | 18,200 | 20,078 | 22,024 |
| Operating Profit | 3,874 | 3,768 | 6,470 | 7,933 | 8,061 |
| OPM % | 20% | 17% | 26% | 28% | 27% |
| Other Income | 335 | 555 | 971 | 909 | 927 |
| Interest | 97 | 96 | 143 | 171 | 234 |
| Depreciation | 1,229 | 1,165 | 1,250 | 1,470 | 1,519 |
| Profit before tax | 2,884 | 3,061 | 6,048 | 7,201 | 7,234 |
| Tax % | 32% | 29% | 25% | 23% | |
| Net Profit | 1,952 | 2,182 | 4,507 | 5,578 | 5,425 |
| EPS in Rs | 23.47 | 26.23 | 54.14 | 66.87 | 64.00 |
| Dividend Payout % | 21% | 23% | 15% | 12% |
Dr Reddy Balance Sheet
| Value In ₹Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
| Equity Capital | 83 | 83 | 83 | 83 | 83 |
| Reserves | 17,558 | 19,129 | 23,203 | 28,171 | 30,666 |
| Borrowings | 3,031 | 3,384 | 1,347 | 2,002 | 4,854 |
| Other Liabilities | 5,915 | 7,149 | 7,576 | 8,523 | 11,125 |
| Total Liabilities | 26,588 | 29,746 | 32,209 | 38,780 | 46,728 |
| Fixed Assets | 8,206 | 8,122 | 9,219 | 10,426 | 17,254 |
| CWIP | 1,565 | 1,293 | 1,030 | 1,419 | 1,852 |
| Investments | 2,212 | 2,616 | 4,986 | 4,930 | 3,663 |
| Other Assets | 14,605 | 17,715 | 16,974 | 22,004 | 23,960 |
| Total Assets | 26,588 | 29,746 | 32,209 | 38,780 | 46,728 |
Dr Reddy Ltd Shareholding Pattern
| Value In ₹Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
| Promoters | 26.74% | 26.72% | 26.69% | 26.65% | 26.64% |
| FIIs | 29.03% | 25.16% | 27.25% | 29.13% | 27.53% |
| DIIs | 14.90% | 24.78% | 23.05% | 18.31% | 21.48% |
| Public | 28.99% | 23.07% | 22.78% | 25.73% | 24.20% |
| Others | 0.35% | 0.28% | 0.22% | 0.17% | 0.16% |
| No. of Shareholders | 2,21,107 | 2,63,803 | 2,32,715 | 2,55,500 | 3,10,403 |
Dr Reddy Dividends History
| Announcement Date | Ex-Dividend Date | Dividend Type | Dividend (Rs) |
| 07 May, 2024 | 16 Jul, 2024 | Final | 40.00 |
| 10 May, 2023 | 11 Jul, 2023 | Final | 40.00 |
| 19 May, 2022 | 11 Jul, 2022 | Final | 30.00 |
| 14 May, 2021 | 09 Jul, 2021 | Final | 25.00 |
| 20 May, 2020 | 13 Jul, 2020 | Final | 25.00 |
| 17 May, 2019 | 15 Jul, 2019 | Final | 20.00 |
| 22 May, 2018 | 16 Jul, 2018 | Final | 20.00 |
| 12 May, 2017 | 17 Jul, 2017 | Final | 20.00 |
| 13 May, 2016 | 18 Jul, 2016 | Final | 20.00 |
| 12 May, 2015 | 10 Jul, 2015 | Final | 20.00 |
| 13 May, 2014 | 11 Jul, 2014 | Final | 18.00 |
| 14 May, 2013 | 12 Jul, 2013 | Final | 15.00 |
| 11 May, 2012 | 28 Jun, 2012 | Final | 13.75 |
| 13 May, 2011 | 30 Jun, 2011 | Final | 11.25 |
| 06 May, 2010 | 02 Jul, 2010 | Final | 11.25 |
| 18 May, 2009 | 03 Jul, 2009 | Final | 6.25 |
| 20 May, 2008 | 04 Jul, 2008 | Final | 3.75 |
| 18 May, 2007 | 06 Jul, 2007 | Final | 3.75 |
| 08 Jun, 2006 | 07 Jul, 2006 | Final | 5.00 |
| 06 May, 2005 | 07 Jul, 2005 | Final | 5.00 |
Dr Reddy Splits History
| Announcement Date | Ex-Split Date | Old FV | New FV | Remarks |
| 27 Jul, 2024 | 28 Oct, 2024 | 5 | 1 | For every share held, the holder will receive 5 shares post the split adjustment. |
| 31 Jul, 2001 | 10 Oct, 2001 | 10 | 5 | For every share held, the holder will receive 2 shares post the split adjustment. |
Dr Reddy Bonus History
| Announcement Date | Ex-Bonus Date | Bonus Ratio | Remarks |
| 31 May, 2006 | 28 Aug, 2006 | 1:1 | For every 1 share held; Holder will receive 1 bonus shares. |
| 24 Mar, 1994 | 08 Apr, 1994 | 2:1 | For every 1 share held; Holder will receive 2 bonus shares. |
| 30 Sep, 1992 | 04 Dec, 1992 | 1:1 | For every 1 share held; Holder will receive 1 bonus shares. |
| 03 Dec, 1991 | – | 1:2 | For every 2 share held; Holder will receive 1 bonus shares. |
Dr Reddys Labs Peers comparison
| Sector: Pharmaceuticals | Industry: Pharmaceuticals – Indian – Bulk Drugs & Formln | ||||
| Name | P/E | Mar Cap₹Cr. | Div Yld% | NP Qtr₹Cr. | ROCE% |
| Sun Pharma.Inds | 38.13 | 427297.56 | 0.76 | 3037.33 | 17.32 |
| Cipla | 26.90 | 123879.68 | 0.85 | 1305.01 | 22.80 |
| Mankind Pharma | 51.20 | 102617.59 | 0.00 | 634.43 | 24.57 |
| Dr Reddy’s Labs | 18.79 | 100318.08 | 0.67 | 1341.90 | 26.53 |
| Zydus Lifesci. | 22.72 | 97197.17 | 0.31 | 920.20 | 22.34 |
| Lupin | 35.62 | 93554.72 | 0.39 | 859.48 | 15.72 |
| Aurobindo Pharma | 20.30 | 73980.61 | 0.36 | 816.95 | 14.10 |
| Median: 76 Co. | 33.74 | 3330.53 | 0.08 | 18.43 | 14.66 |
FAQs
Q1. Dr Reddy Share Price Target 2025?
Ans: The share price target for Dr. Reddy’s Laboratories in 2025 is expected to reach ₹1480 as the first target and ₹1650 as the second target. These targets reflect the company’s strong market presence and consistent growth in the pharmaceutical sector.
Q2. Dr Reddys Labs Share Price Target 2026?
Ans: By 2026, the share price is projected to achieve ₹1800 as the first target and ₹1910 as the second target, driven by its focus on innovation and expansion into global markets.
Q3. Dr Reddy Share Price Target 2027?
Ans: In 2027, Dr. Reddy’s share price is anticipated to reach ₹2150 as the first target and ₹2300 as the second target, indicating continued growth supported by product diversification and R&D efforts.
Q4. Dr Reddy Share Price Target 2028?
Ans: The share price for 2028 is expected to hit ₹2550 as the first target and ₹2730 as the second target, showcasing robust growth fueled by its pipeline of new pharmaceutical products.
Q5. Dr Reddys Labs Share Price Target 2029?
Ans: For 2029, the share price is forecasted to achieve ₹2950 as the first target and ₹3050 as the second target, reflecting steady performance and market expansion.
Q6. Dr Reddy Share Price Target 2030?
Ans: By 2030, Dr. Reddy’s share price is anticipated to reach ₹3200 as the first target and ₹3470 as the second target, signaling sustainable growth and industry leadership.
Q7. Dr Reddy Share Price Target 2035?
Ans: In 2035, the share price is estimated to reach ₹4900 as the first target and ₹5640 as the second target, highlighting the company’s significant long-term growth potential.
Q8. Dr Reddy Share Price Target 2040?
Ans: By 2040, Dr. Reddy’s share price is projected to achieve ₹7500 as the first target and ₹8150 as the second target, reflecting its position as a global leader in the pharmaceutical sector.
Q9. Who is the current CEO of Dr Reddy?
Ans: The global CEO of Dr. Reddy’s Laboratories is Erez Israeli, who leads the company’s strategic initiatives and global operations. In addition, Milan Kalawadia recently became CEO of the North America business.
Q10. Where does Dr. Reddy’s operate?
Ans: Dr. Reddy’s Laboratories has a global footprint with a presence in more than 20 countries, including major markets like: India: The primary market for its branded generics, United States and Europe: Focused on generics and biosimilars, Russia and CIS: A stronghold for its branded products.
TradeWatch360 is a premier platform dedicated to providing real-time insights, trends, and updates in the stock market. It is designed to support both new and seasoned investors by delivering timely and actionable information across a range of asset classes, including stocks, futures, commodities, and global markets.